Equine VEGF-A Recombinant Protein

Catalog Number:: RP0341E
Availability:: In stock
Application:: Cell Culture, ELISA Standard, ELISpot Control, Western Blot Control
100% Homology:: Equus asinus (ass), Equus caballus (horse)

Product Description

Equine VEGF-A (catalog RP0341E) is a yeast-derived growth factor supplied lyophilized without carrier protein in 10% trehalose; it has no affinity tags and is naturally endotoxin-free, and should be reconstituted in sterile PBS that contains at least 0.1% carrier protein. The protein is ~19.2 kDa, 164 amino acids long (full sequence provided), and >98% pure by SDS-PAGE, with 100% amino-acid homology to horse and ass. Store at -20°C (stable up to twelve months from date of receipt; working aliquots with carrier protein stable ~3 months) and avoid repeated freeze/thaw cycles. Product origin is the USA. It is commonly used to study angiogenesis, endothelial-cell proliferation, migration, vascular permeability and VEGF-receptor signaling; typical experimental uses include endothelial cell culture stimulation and proliferation/tube-formation assays, receptor-binding and signaling studies, ELISA and neutralization assays, flow-cytometry and Western blot controls, and antibody generation/validation. Kingfisher Biotech products are supplied for research applications and are not intended for medicinal, diagnostic, or therapeutic use.

Specifications

Amino Acid Sequence	APMAEGEHKT HEVVKFMDVY QRSYCRPIET LVDIFQEYPD EIEYIFKPSC VPLMRCGGCC NDEGLECVPT AEFNITMQIM RIKPHQSQHI GEMSFLQHSK CECRPKKDKA RQENPCGPCS ERRKHLFVQD PQTCKCSCKN TDSRCKARQL ELNERTCRCD KPRR (164)
Endotoxin	Naturally endotoxin-free

Properties

Storage Conditions	-20°C
Molecular Weight	19.2 kda
Purity	>98% as visualized by SDS-PAGE analysis.
Country Of Origin	USA

Background Info

Equine Vascular Endothelial Growth Factor A (VEGF-A) is a member of the vascular endothelial growth factor (VEGF) family, which includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth factor (PlGF)-key regulators of angiogenesis, vascular development, and endothelial cell function. In horses (Equus caballus), VEGF-A is produced by a variety of cells including endothelial cells, macrophages, fibroblasts, epithelial cells, and muscle cells, particularly in response to hypoxia, inflammation, exercise-induced stress, or tissue injury. VEGF-A exerts its biological effects primarily through binding to VEGF receptor-1 (VEGFR-1/Flt-1) and VEGF receptor-2 (VEGFR-2/KDR) on endothelial cells, activating intracellular signaling pathways such as MAPK/ERK, PI3K/AKT, and PLCγ, which promote endothelial cell proliferation, migration, vascular permeability, and formation of new blood vessels. In equine physiology, VEGF-A plays important roles in vascular development, wound healing, and tissue regeneration, particularly in musculoskeletal tissues such as tendon, ligament, and bone. VEGF-A is also involved in exercise-induced vascular adaptation in skeletal muscle, which is important for athletic performance in horses. Dysregulated VEGF signaling may contribute to abnormal tissue remodeling or tumor angiogenesis in certain equine diseases. Because horses are frequently studied in sports medicine, musculoskeletal injury repair, and regenerative therapies, equine VEGF-A is an important focus in research on angiogenesis, tissue healing, and vascular adaptation relevant to equine health and performance.

Choose a size

Please choose a size to see price

RELATED MEDIA